ALSO NOTED: FDA interviews for Singulair psych effects; Wal-Mart offers 90-day scrips for $10;

> The FDA is collecting personal stories of suicide and other unusual side effects from Merck's allergy med Singulair as part of a nine-month review of the drug's safety; parents of one teen are lobbying for a "black box" warning of mood changes and suicidal thoughts. Report

> Wal-Mart said it's rolling out a new phase of its generic-drugs program, promising to fill many 90-day scrips for $10 and offering several women's meds--including the cancer drug Tamoxifen--for $9 a month or $24 for a 90-day supply. Report

> New Zealand's government drug-buying agency has started a court-ordered study on whether it should fund 12-month courses of the breast cancer drug Herceptin, rather than the nine-week course it now pays for. Report

> GlaxoSmithKline inked a deal to sell Japan-based Astellas Pharma's injectable anti-fungal Micafungin in India. Report

> A slowdown in pharma has braked sales of Applied Biosystems' mass spectrometers, depressing overall quarterly revenue growth to 4.3 percent. Report

> Boehringer Ingelheim got European approval for use of its Aptivus drug in HIV-positive patients resistant to commonly prescribed meds. Report

> Employees at a former Merck plant in Karachi, Pakistan, are balking at the loss of their stock options after the plant was sold to Organon BioSciences. Report

> Pfizer is still hunting for buyers for two factories in Cork, Ireland, some 15 months after putting those facilities on the market. Report

> Alpharma posted a tenfold rise in first-quarter profits, to $163.1 million, on a leap in revenues from its Flector pain patch. Report

> Novartis' painkiller Voveran has overtaken Pfizer's Corex cough syrup as the fastest-selling drug in India. Report

> In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. Report

> Discovery Labs has been dealt another blow in its quest to gain approval for Surfaxin, a treatment for premature infant respiratory distress syndrome. Report

> Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Report

> Critical Therapeutics is merging with Cornerstone BioPharma Holdings, a specialty pharmaceutical company that develops treatments for respiratory disorders. Report

And Finally... Another windfall from the Neurontin marketing settlement: Consumers Union has nabbed a $4.4 million grant to distribute free, unbiased prescription drug info. Report